相关实验视频
Updated: Jan 7, 2026

07:57
Assessing Whole-Body Lipid-Handling Capacity in Mice
Published on: November 24, 2020
4.6K
在工作中断的坐着可以改变食后葡萄糖,甘油三和非化脂肪酸 (NEFA)
1Department of Community Medicine, Faculty of Medicine, Medical Campus, Universiti Sultan Zainal Abidin, Kuala Terengganu, Terengganu, Malaysia. ismunira@unisza.edu.my.
The Medical journal of Malaysia
|December 25, 2025
概括
打破长时间的坐着和大力地爬楼梯或轻轻步行可以改善食后葡萄糖和甘油三水平. 强度更高的中断显示,久坐不动的工作人员的健康益处更大.
科学领域:
- 运动生理学 运动生理学
- 代谢健康 代谢健康
- 职业健康 职业健康 职业健康
背景情况:
- 长时间坐着是与心脏代谢风险相关的重大健康问题.
- 工作场所的干预措施往往包括中断坐着以减轻健康影响.
- 中断强度对代谢标志物的影响需要进一步研究.
研究的目的:
- 检查不同强度的中断式坐着对食后葡萄糖,甘油三和非化脂肪酸 (NEFA) 的影响.
- 为了比较对不间断的坐着的代谢反应与因轻度强度走路或强烈强度爬楼梯而中断的坐着.
主要方法:
- 一个随机交叉试验,涉及24名超重/肥胖成年人.
- 参与者接受了三个条件:不间断地坐着,坐着被轻步 (3公里/小时) 打断,坐着被大力爬楼梯 (60步/分钟) 打断.
- 干预包括每20分钟进行2分钟的治疗,每餐后7小时,每小时收集一次血液样本.
主要成果:
- 与不间断的坐着相比,大力爬楼梯导致更低的食后葡萄糖峰值和减弱的NEFA减少.
- 与不间断的坐着相比,轻度散步显著降低了食后甘油三水平.
结论:
- 间歇性坐着,特别是与爬楼梯等更高强度的活动一起,提供了更大的食后代谢改善.
- 工作场所策略包括更高强度的活动休息,可以有效地打击久坐行为风险.
相关概念视频
Metabolic States of the Body: The Postabsorptive State
1.2K
The postabsorptive state usually starts about four hours after a meal and lasts until the next meal is eaten. During this time, the digestive system stops absorbing nutrients, and the body uses stored energy reserves to maintain stable blood glucose levels.
Initially, glycogen stored in the liver is broken down to release glucose into the bloodstream, while glycogen in the muscles is broken down to supply glucose for energy directly within the muscle cells. As glycogen stores diminish,...
Initially, glycogen stored in the liver is broken down to release glucose into the bloodstream, while glycogen in the muscles is broken down to supply glucose for energy directly within the muscle cells. As glycogen stores diminish,...
1.2K
Metabolic States of the Body: The Absorptive State
1.3K
During the absorptive state, which lasts approximately four hours after a meal, the body absorbs nutrients from the gastrointestinal tract. The carbohydrates, proteins, and lipids we consume are broken down into monosaccharides, amino acids, and free fatty acids for absorption. While carbohydrates and proteins are absorbed as-is, lipids are absorbed in their broken-down forms and then re-esterified into triglycerides within enterocytes before being packaged into chylomicrons. These absorbed...
1.3K
Glucose Homeostasis: Regulation of Blood Glucose
3.7K
Carbohydrates consumed through foods are converted into glucose, a crucial energy source for the body. In the prandial state, high blood glucose levels stimulate the secretion of insulin from the pancreas. Insulin inhibits hepatic glucose production and stimulates glucose uptake and metabolism by muscle and adipose tissue. The excess glucose is converted into glycogen and stored in the liver and muscles.
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
3.7K
Dipeptidyl Peptidase 4 Inhibitors
540
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
540
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
496
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
496
Glucagon-like Receptor Agonists
809
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
809

